GYRE 8-K 2026-11-05

GYRE THERAPEUTICS, INC. (GYRE) 8-K dated 2026-11-05 — accession 0001193125-26-449985.

GYRE THERAPEUTICS, INC. (GYRE) is a biotechnology company listed on NASDAQ.

GYRE THERAPEUTICS, INC. filed a 8-K on 2026-11-05. Accession 0001193125-26-449985.

This 8-K covers: Results of operations (Item 2.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported GYRE revenue for 2025-12-31 was $116.6M. Net income was $9.9M. Revenue was up 10.2% from 2024-12-31 to 2025-12-31. GYRE currently screens at market cap $589.9M.

Not investment advice. The GYRE SEC hub lists recent forms. The stock page is the research view.